Vedolizumab for ulcerative colitis: Real world outcomes from a multicenter observational cohort of Australia and Oxford
Samba Siva Reddy Pulusu, Ashish Srinivasan, Krupa Krishnaprasad, En-Hsiang Cheng, Jakob Begun, Charlotte Keung, Daniel R. van Langenberg, Lena Thin, Tamara Mogilevski, Peter De Cruz, Graham Radford‐Smith, Emma Flanagan, Sally Bell, Soleiman Kashkooli, Miles Sparrow, Simon Ghaly, Peter A. Bampton, E Sawyer, Susan J. Connor, Quart-ul-ain Rizvi, Jane M. Andrews, Gillian Mahy, Paola Chivers, Simon Travis, Ian C. Lawrance
Abstract
BACKGROUND: integrins is approved for use in adult moderate to severe ulcerative colitis (UC) patients. AIM: To assess the efficacy and safety of VDZ in the real-world management of UC in a large multicenter cohort involving two countries and to identify predictors of achieving remission. METHODS: A retrospective review of Australian and Oxford, United Kingdom data for UC patients. Clinical response at 3 mo, endoscopic remission at 6 mo and clinical remission at 3, 6 and 12 mo were assessed. Cox regression models and Kaplan Meier curves were performed to assess the time to remission, time to failure and the covariates influencing them. Safety outcomes were recorded. RESULTS: < 0.001). 32 patients (11%) had colectomy by 12 mo. CONCLUSION: VDZ was safe and effective with 60% of UC patients achieving clinical remission at 12 mo and prior anti-TNF exposure influenced this outcome.